This model contains a ten year commercial forecast of hepatitis B drug sales by country, class, molecule and brand across the US, Japan, France, Germany, Italy, Spain, UK and Turkey.
Reasons to Purchase
*Understand the changing market dynamics of hepatitis B drugs and success factors for leading brands.
*Assess the impact of events such as patent expiries on the overall hepatitis B market.
*Obtain full, country, class and product-specific forecasts of currently marketed drugs from 2009 to 2019 for all seven major markets and Turkey.
#N/A
Other selected research from the 'Markets' category:
The Pharmaceutical Company Outlook to 2011: Financial and Strategic Analysis of the Sales Outlook for Big Pharma, Mid Pharma, Japan Pharma and Biotech
Based on an analysis of 46 companies and 1,000+ products, Datamonitor forecasts that pharmaceutical industry ethical sales will increase at a modest 4.9% CAGR 200511. However, behind this industry average figure there are strategic segments of the market that offer double-digit growth rates through barriers against generic competition and the opportunity for aggressive indication broadening. Learn More
Pharmaceuticals in China
Pharmaceuticals in China industry profile is an essential resource for top-level data and analysis covering the pharmaceuticals industry. Learn More